According to The New York Times, health experts were “shocked” when the United Kingdom made a change to its guidelines in January to suggest that COVID-19 vaccines could be mixed.
New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases.
While SARS-CoV-2 and similar coronaviruses are considered respiratory pathogens, a subset of patients with COVID-19 have presented with extrapulmonary disease along with neurological complications.
A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.
For many employees early in their career, the idea of one day becoming a leader in their workplace is a goal they hope to achieve, and they may even spend time envisioning themselves in the role.
UCSF, Berkeley, UCLA to launch sickle cell trial using CRISPR
Scientists at UC San Francisco (UCSF), UC Berkeley, and UC Los Angeles (UCLA) have received U.S. Food and Drug Administration approval to jointly launch an early phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient’s own blood-forming stem cells.
Even before COVID-19, telehealth services were gaining in popularity. But the SARS-CoV-2 pandemic fully opened the door to widespread use of mobile healthcare (mHealth) technologies. This has had an on-going impact on clinical laboratories.
A substantial proportion of people with opioid use disorder in the United States have not received any form of medication-assisted treatment, according to results of a model-based cost-effectiveness analysis published in JAMA Psychiatry.
We need your help to grow this newsletter! Please pass along the subscription link to any colleague you think would benefit from hearing about med lab news.